Andrea Chicca

Andrea holds a Ph.D. in Pharmacology with over 15 years of experience. He was appointed Adjunct Professor at the University of Bern's Medical Faculty and completed a Master of Advanced Studies in Translational Medicine and Biomedical Entrepreneurship. After his post-doctoral studies, Andrea worked as a scientific advisor at Chiesi Pharmaceuticals, gaining expertise in preclinical and clinical drug development. He later joined Prof. J. Gertsch's research group at the University of Bern, advancing to senior scientist and principal investigator. There, he contributed to the NCCR TransCure project, focusing on membrane transporters in drug discovery. Andrea has co-authored over 50 peer-reviewed scientific articles and made notable contributions to endocannabinoid research and the development of Selective Endocannabinoid Reuptake Inhibitors (SERIs). He is also a co-founder and CEO of Synendos Therapeutics.